Purpose: The purpose of this study was to investigate the reliability and the clinical applicability of the adenosine-triphosphate-based chemotherapy response assay (ATP-CRA) as a method of determining in vitro chemosensitivity in patients with gastric cancer. Materials and Methods: A total of 243 gastric cancer tissue samples were obtained from gastrectomies performed between February 2007 and January 2010. We evaluated the effectiveness of the ATP-CRA assay in determining the chemosensitivity of gastric cancer specimens using eleven chemotherapeutic agents -etoposide, doxorubicin, epirubicin, mytomicin, 5-fluorouracil, oxaliplatin, irinotecan, docetaxel, paclitaxel, methotraxate, and cisplatin -for chemosensitivity studies using ATP-CRA. We assessed the failure rate, the cell death rate, and the chemosensitivity index. Results: The failure rate of ATP-CRA was 1.6% (4/243). The mean coefficient of variation for triplicate ATP measurements was 6.5%.
Introduction
Gastric cancer is the fourth leading cause of cancer death worldwide.(1) Gastric cancer is the most prevalent cancer in Korea and the treatment of gastric cancer patients accounts for the highest percentage of the national health expenditure, 19 .1% of all cancerrelated health insurance payments.(2) Even after curative resection, advanced gastric cancer patients are given postoperative chemotherapy due to the high risk of recurrence because by adding chemotherapy we may expect better patient survival than with surgery alone. (3) (4) (5) (6) For gastric cancer, many chemotherapeutic agents are used.
However, the chemotherapeutic effect of these drugs on gastric cancer is variable. Furthermore, neither a uniformly effective nor a standard chemotherapeutic regimen for gastric cancer has been clearly established. In efforts to improve the response rate to chemotherapy, in vitro chemosensitivity tests have been employed to select the optimal chemotherapeutic agents for individual patients. underwent initial washing with 70% ethanol before being quantified and minced to a size less than 1 mm mechanical disaggregation.
Then, for enzymatic disaggregation, they were incubated at 37 o C with 5% CO 2 for 12 to 16 hours with extracellular matrix degrading enzymes such as dispase (Sigma, St Louis, Mo, USA), pronase (Sigma, St Louis, Mo, USA) and DNase (Sigma, St Louis, Mo, USA). Cells were harvested using a cell strainer (BD Falcon, Bedford, MA, USA). To remove red blood cells, normal cells, and excess debris, the cell suspensions were subjected to Ficoll-Hypaque (1077-1, Sigma, St Louis, Mo, USA) gradient centrifugation at 400 g for 15 min and anti-CD45 antibody conjugated magnetic beads (Miltenyi Biotech, Auburn, CA, USA). Trypan blue exclusion test was used to determine the viability of isolated cells.
After dilution of the separated tumor cells to 2,000~20,000 viable cells/100 μl using IMDM (GIBCO BRL, Rockville, MD, USA), including 10% FBS, they were seeded in triplicate to a 96-well ultra low attachment microplate (Costar, Cambridge, MA, USA), which restricts the growth of normal cells. In the treated groups, 100 μl of chemotherapeutic agents were added to the seeded cells; while in the untreated control groups, 100 μl of IMDM without chemotherapeutic agents was added to 3~6 wells of the microplate.
The test drug concentrations were determined based on the peak plasma concentrations according to previous reports and preliminary training set experiments: etoposide (3.57 μg/ml), doxorubicin (1.5 μg/ml), epirubicin (1.2 μg/ml), mitomycin (0.2 μg/ml), 5-FU (10 μg/ml), oxaliplatin (2.9 μg/ml), irinotecan (4.7 μg/ml), docetaxel (3.7 μg/ml), paclitaxel (8.5 μg/ml), MTX (0.37 μg/ml) and cisplatin Mean luminescence in treated cells )×100 Mean luminescence in untreated control of the untreated control group which had a measurement less than numbers of cells were harvested or cell culture failed due to microorganism contamination, the test was also regarded as failure.
Statistical analysis
All statistical analyses were performed using the "Statistical Package for Social Science (SPSS)" version 18.0 for windows (SPSS Inc., Chicago, IL, USA). The difference of the chemosensitivity index between the early and the advanced gastric cancer groups, the serosa involved and the serosa non-involved groups, and the lymph node negative and the lymph node positive groups were compared using the Student t-test. A P-value＜0.05 was considered statistically significant.
Results

Clinicopathologic characteristics
Of the 243 patients, 4 of the patients were excluded from the study due to failure in the chemosensitivity test. The clinicopathologic features those 239 patients are presented in Table 1 
In vitro chemosensitivity test results
Of the 243 patients who underwent gastrectomy, 4 cases failed the chemosensitivity test. Test failure rate was 1. The cytotoxic effect for test drug concentrations of the che- and the narrowest range (0~62.7%). Table 3 shows each CI which indicates chemosensitivity of anticancer drug calculated by the formula described in the Method section. The values of CI were heterogeneous among specimens. 5-FU = 5-fluorouracil; MTX = methotrexate. *Chemosensitivity index (CI) = 300-sum%Inhibition at 0.2-, 1-, and 5-fold of test drug concentration).
The most active chemotherapeutic agent was etoposide which most frequently had the highest (top-ranked) chemosensitivity, 31.9%
(51/160) for the tested specimens. When we compared the cell death rates according to the pathologic characteristics, there was a significant difference in cell death rates according to lymph node metastasis. The lymph node negative group showed significantly higher cell death rates than the lymph node positive group in doxorubicin, epirubicin, and mitomycin (P＜0.05, respectively) ( Table 4) .
Discussion
From Our study has several limitations. A few of the anti-cancer agents which showed high cell death rates may be difficult to evaluate in practice since they are not included in clinically used regimens. In addition, since we studied the ATP-CRA only for single agents, the effect of combining anti-cancer drugs could not be investigated. Thus, we cannot estimate the interaction between the drugs and different pharmacokinetic effects of individual pa-tients. Nevertheless, our study provided the possibility of an in vitro detection of the chemotherapeutic agents with a potential for a high success rate. From these results, studies on survival benefits of various anti-cancer agents for gastric cancer based on ATP-CRA results and a prospective study comparing in vitro chemosensitivity assay-guided chemotherapy with empiric chemotherapy are warranted.
In conclusion, ATP-CRA is a stable and clinically applicable in vitro chemosensitivity test with a low failure rate. The clinical usefulness of ATP-CRA should be evaluated by prospective studies comparing regimen guided by ATP-CRA with the empirical regimen.
